Denali Therapeutics Inc. Contracts & Agreements
55 Contracts & Agreements
- Business Finance (20 contracts)
- Business Operations (13)
- Human Resources (8)
- Intellectual Property (2)
- Real Estate (2)
- Uncategorized (10)
- Description of the Registrants Common Stock (Filed With SEC on February 28, 2024)
- Compensation Recovery Policy (Clawback Policy) (Filed With SEC on February 28, 2024)
- Denali Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities as amended through March 31, 2023 (Filed With SEC on February 28, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on February 27, 2024)
- Securities Purchase Agreement, dated February (Filed With SEC on February 27, 2024)
- Nominating Agreement by and among the Company and Investor (Filed With SEC on February 27, 2024)
- Amendment to Definitive LRRK2 Agreement and Waiver of and Amendment to Right of First Negotiation, Option, and License Agreement (Filed With SEC on November 7, 2023)
- Amendment No. 9 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated December 7, 2022 (Filed With SEC on February 27, 2023)
- Amendment No. 8 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 8, 2022 (Filed With SEC on February 27, 2023)
- Amendment No. 7 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated March 29, 2021 (Filed With SEC on February 27, 2023)
- Description of the Registrants Common Stock (Filed With SEC on February 27, 2023)
- Underwriting Agreement, dated as of October (Filed With SEC on October 20, 2022)
- Equity Distribution Agreement between the Company and Goldman Sachs & Co. LLC, SVB Securities LLC and Cantor Fitzgerald & Co., dated as of February 28, 2022 (Filed With SEC on February 28, 2022)
- Amended and Restated Outside Director Compensation Policy (Filed With SEC on February 28, 2022)
- Description of the Registrants Common Stock (Filed With SEC on February 28, 2022)
- Side Letter between the Registrant and F-star Gamma Limited, dated June 30, 2021 (Filed With SEC on August 4, 2021)
- Amended and Restated Outside Director Compensation Policy (Filed With SEC on May 5, 2021)
- Amendment No. 6 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October... (Filed With SEC on February 26, 2021)
- Amendment No. 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October... (Filed With SEC on February 26, 2021)
- Amendment No. 5 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October... (Filed With SEC on February 26, 2021)
- Amended and Restated Outside Director Compensation Policy (Filed With SEC on February 26, 2021)
- Description of the registrants common stock (Filed With SEC on February 26, 2021)
- Form of Amended and Restated Change in Control and Severance Plan (Filed With SEC on November 5, 2020)
- Definitive R (Filed With SEC on November 5, 2020)
- Definitive LRRK2 Collaboration and License Agreement (Filed With SEC on November 5, 2020)
- Standstill and Stock Restriction Agreement between the Registrant and Biogen Inc., dated September 22, 2020 (Filed With SEC on November 5, 2020)
- Provisional LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated August 5, 2020 (Filed With SEC on November 5, 2020)
- Common Stock Purchase Agreement between the Registrant and Biogen Inc., dated August 5, 2020 (Filed With SEC on November 5, 2020)
- Amended and Restated Outside Director Compensation Policy (Filed With SEC on May 7, 2020)
- Description of the registrants common stock (Filed With SEC on February 27, 2020)
- Underwriting Agreement, dated as of January 28, 2020, among Denali Therapeutics Inc. and Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, and Jefferies LLC, as representatives... (Filed With SEC on January 29, 2020)
- Amendment No. 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October... (Filed With SEC on November 8, 2018)
- Amendment No. 4 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October... (Filed With SEC on November 8, 2018)
- First Amendment to Lease between the Registrant and HCP Oyster Point III LLC, dated May 2, 2018 (Filed With SEC on August 9, 2018)
- Amended and Restated Licence Agreement between F-star Gamma Limited and F-star Biotechnology Limited, dated August 24, 2016 (Filed With SEC on August 9, 2018)
- Side Letter between the Registrant, F-Star Gamma Limited, F-Star Biotechnology Limited and f-star Biotechnologische Forschungs-und Entwicklungsges m.b.H., dated May 21, 2018 (Filed With SEC on August 9, 2018)
- Share Purchase Agreement between the Registrant, certain shareholders of F-star Gamma Limited and Shareholder Representative Services LLC, dated May 30, 2018 (Filed With SEC on August 9, 2018)
- Common Stock Purchase Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018 (Filed With SEC on March 19, 2018)
- Amendment No. 2 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No. 1 on October... (Filed With SEC on March 19, 2018)
- Standstill and Stock Restriction Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated February 23, 2018 (Filed With SEC on March 19, 2018)
- Option and Collaboration Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018 (Filed With SEC on March 19, 2018)
- 2017 Employee Stock Purchase Plan and form of agreement thereunder, to be in effect upon the completion of this offering (Filed With SEC on December 7, 2017)
- 2017 Employee Stock Purchase Plan and form of agreement thereunder, to be in effect upon the completion of this offering (Filed With SEC on November 27, 2017)
- 2017 Equity Incentive Plan and forms of agreements thereunder, to be in effect upon the completion of this offering (Filed With SEC on November 27, 2017)
- Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on November 27, 2017)
- Specimen common stock certificate of the Registrant (Filed With SEC on November 27, 2017)
- Form of Underwriting Agreement, including Form of Lock-up Agreement (Filed With SEC on November 27, 2017)
- Investors Rights Agreement among the Registrant and certain of its stockholders, dated May 8, 2015, as amended on June 4, 2015, July 22, 2015 and June 22, 2016 (Filed With SEC on November 13, 2017)
- 2015 Stock Incentive Plan, as amended, and forms of agreement thereunder (Filed With SEC on November 13, 2017)
- Offer Letter between the Registrant and Ryan J. Watts, Ph.D., dated November 10, 2017 (Filed With SEC on November 13, 2017)
- Offer Letter between the Registrant and Alexander O. Schuth, M.D., dated November 10, 2017 (Filed With SEC on November 13, 2017)
- Offer Letter between the Registrant and Steve E. Krognes, dated November 10, 2017 (Filed With SEC on November 13, 2017)
- Offer Letter between the Registrant and Carole Ho, M.D., dated November 10, 2017 (Filed With SEC on November 13, 2017)
- Lease Agreement between the Registrant and HCP Oyster Point III LLC, dated September 24, 2015 (Filed With SEC on November 13, 2017)
- Exclusive License Agreement between the Registrant and Genentech, Inc., dated June 17, 2016 (Filed With SEC on November 13, 2017)